Alimera Sciences Stock News

ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022

ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

Alimera Sciences press release (ALIM): Q4 GAAP EPS of -$0.59 misses by $0.17.Revenue of $13.95M (+1.3% Y/Y) beats by $0.55M.

Fourth Quarter Highlights:

Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q4 2021 Results - Earnings Call Transcript

Alimera Sciences (NASDAQ:ALIM) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.28 and the consensus

Alimera Sciences (ALIM) reported three-year results of a study, called PALADIN, of the ILUVIEN implant in patients with diabetic macular edema ((DME)), an eye complication in people

Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time

Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time

ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partne

ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners

ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission